A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection

Due to the scarcity of data on prognostic and predictive influence on CCA, epidemiological studies evaluating these factors need to be developed in patients with CCA. Therefore, the investigators want to evaluate the profile of patients in the real world and from various parts of the world, describing prognostic factors such as CD4 dosage, time of HIV infection, evaluation of viral load, diagnosis of AIDS, geographic region of diagnosis and treatment, clinical staging, medications concomitant with QRT (risk of drug interactions), comorbidities (possible impact on dose-intensity), use of HAART, time of use of HAART, radiotherapy modality (conventional 3D vs Modulated Beam Intensity \[IMRT\], response to Nigro vs CTII regimens, as well as comparing clinical outcomes with patients without HIV infection.

NCT Number	NCT05328765
Lead Sponsor	Latin American Cooperative Oncology Group
Conditions	Anal Squamous Cell Carcinoma, HIV Infections
Enrollment	300 participants
Start Date	2023-06-09
Primary Completion	2025-04-24 (estimated)
Study Completion	2025-04-24 (estimated)
Updated on ClinicalTrials.gov	2025-03-07